Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Arjo ABFRA:A39 +0.87%72 Buyback Yield % is 0.00 as of Jul. 14, 2026. GuruFocus rates FRA:A39 with a GF Score™ of 72/100 and a GF Value™ of €3.25 (Modestly Undervalued). The stock has 5 warning signs investors should review. Among 39 Medical Distribution companies, Arjo AB ranks worse than 2564100% on this metric.
Buyback yield is the net repurchase of shares outstanding over the market capital of the company. It is a measure of shareholder return.
The historical data trend for Arjo AB's Buyback Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:A39 vs MCK, CAH, COR: Buyback Yield % Comparison
For the Medical Distribution subindustry, Arjo AB's Buyback Yield %, along with its competitors' market caps and Buyback Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Arjo AB Buyback Yield % vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, Arjo AB's Buyback Yield % distribution charts can be found below:
* The bar in red indicates where Arjo AB's Buyback Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Arjo AB (FRA:A39) has a Buyback Yield % of 0.00 as of Jul. 14, 2026. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Arjo AB and its competitors. Over the past decade, Arjo AB's Buyback Yield % has ranged from 57.52 to 90.90. According to the industry distribution chart, Arjo AB ranks #999999 out of 39 companies in the Medical Distribution industry.
Is Arjo AB's Buyback Yield % too high?
Arjo AB's current Buyback Yield % is 0.00. Over the past 10 years, this metric has ranged from a low of 57.52 to a high of 90.90. Based on the distribution chart, Arjo AB ranks #999999 out of 39 companies in the Medical Distribution industry, which is in the bottom quartile relative to peers. Overall, Arjo AB has a GF Score™ of 72/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Arjo AB's Buyback Yield % compare to MCK and CAH?
According to the Medical Distribution industry distribution chart, Arjo AB ranks #999999 out of 39 companies for Buyback Yield %. This places Arjo AB in the lower half of its industry. The industry median Buyback Yield % is 0.05. Historically, Arjo AB's own Buyback Yield % has ranged from 57.52 to 90.90 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Buyback Yield % for a Medical Distribution company?
The median Buyback Yield % among Medical Distribution companies is 0.05, based on 39 companies in the industry. Companies in the top quartile (top 25%) have a Buyback Yield % significantly above this median, while those in the bottom quartile fall well below. However, Buyback Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Buyback Yield % mean?
A high Buyback Yield % can signal that a stock is expensive relative to its fundamentals. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Arjo AB and its competitors. For the Medical Distribution industry, the median Buyback Yield % is 0.05 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Arjo AB's current Buyback Yield % is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Arjo AB stock overvalued right now?
Based on GuruFocus' analysis, Arjo AB (FRA:A39) is currently considered Modestly Undervalued. The stock's GF Value™ is €3.25, compared to a current price of €2.33 — trading 28.4% below its estimated fair value. The current Buyback Yield % is 0.00. Arjo AB's overall GF Score™ is 72/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Buyback Yield % calculated?
Buyback Yield % is calculated from a company's financial statements. For Arjo AB (FRA:A39), the current Buyback Yield % is 0.00 as of Jul. 14, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Arjo AB (FRA:A39) Overvalued in 2026?
Based on GuruFocus' analysis, Arjo AB stock appears to be undervalued.
The current stock price of €2.33 is trading 28.4% below its estimated GF Value™ of €3.25.
GuruFocus considers Arjo AB to be Modestly Undervalued.
Key valuation signals for FRA:A39:
Buyback Yield %: 0.00
GF Value™: €3.25 vs. price of €2.33 (28.4% below fair value)
No single metric tells the full story. See the FRA:A39 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Arjo AB is a supplier of medical devices, services, and solutions in Sweden. It serves its services to private and public institutions with acute care and long-term care. The company's offering includes products and solutions for patient handling, hygiene, disinfection, medical beds, therapeutic surfaces, venous thromboembolism (VTE) prevention and diagnostics. The company includes segments: Global Sales, North America, Diagnostics.
72GF Score
Get the complete analysis for FRA:A39
Buyback Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:A39 has been successfully added to your 
